Prospects of Disease-Modifying Osteoarthritis Drugs
Rheumatic Disease Clinics of North America · 2024-08 · 50 (3) · 483-518
DOI: 10.1016/j.rdc.2024.03.003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Rheumatic Disease Clinics of North America, 2024-08. Verfasst von Win Min Oo. Beteiligte Einrichtung: Department of Physical Medicine and Rehabilitation, Mandalay General Hospital, University of Medicine, Mandalay, Mandalay, Myanmar; Rheumatology Depa…. Hauptthemen laut MEDLINE: Osteoarthritis, Antirheumatic Agents. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 141 Literaturangaben.
Abstract (Originalsprache)
Osteoarthritis (OA) causes a massive disease burden with a global prevalence of nearly 23% in 2020 and an unmet need for adequate treatment, given a lack of disease-modifying drugs (DMOADs). The author reviews the prospects of active DMOAD candidates in the phase 2/3 clinical trials of drug development pipeline based on key OA pathogenetic mechanisms directed to inflammation-driven, bone-driven, and cartilage-driven endotypes. The challenges and possible research opportunities are stated in terms of the formulation of a research question known as the PICO approach: (1) population, (2) interventions, (3) comparison or placebo, and (4) outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physical Medicine and Rehabilitation, Mandalay General Hospital, University of Medicine, Mandalay, Mandalay, Myanmar; Rheumatology Department, Royal North Shore Hospital, Institute of Bone and Joint Resear…
Zitieren
APA
Oo, W. M. (2024). Prospects of Disease-Modifying Osteoarthritis Drugs. Rheumatic Disease Clinics of North America, 50(3), 483-518. https://doi.org/10.1016/j.rdc.2024.03.003
Vancouver
Oo WM. Prospects of Disease-Modifying Osteoarthritis Drugs. Rheumatic Disease Clinics of North America. 2024;50(3):483-518. doi:10.1016/j.rdc.2024.03.003
BibTeX
@article{Oo2024,
author = {Oo, Win Min},
title = {Prospects of Disease-Modifying Osteoarthritis Drugs},
journal = {Rheumatic Disease Clinics of North America},
year = {2024},
volume = {50},
number = {3},
pages = {483--518},
doi = {10.1016/j.rdc.2024.03.003}
}
EUVIMED